By posting a big gain Friday after pricing an upsized IPO at the top end of its range, ORIC provided another encouraging data point to biotechs seeking to test the public markets, suggesting that investors...

ORIC sets terms for planned IPO In an updated prospectus, oncology company ORIC Pharmaceuticals Inc. proposed to sell 5 million shares at $14-$16 in a planned IPO on NASDAQ. At the midpoint, a sale of...

China’s suspension of the importation and sale of Celgene’s Abraxane by BeiGene following an inspection at a U.S. manufacturing site demonstrates how far the country has come in its drive to ensure safety of drugs,...

It is a truth universally acknowledged, to borrow from Jane Austen, that a single-payer system will say “no” to new technology. If they accept it at all, they do so only when the prices are...

MNC originators took the deepest price cuts in the second round of China’s expanded centralized procurement program for generic and off-patent drugs. A list released Tuesday by China’s Joint Procurement Office showed that 77 winning...

BeiGene announced Tuesday that tislelizumab met the primary endpoint in a Chinese Phase III trial for first-line squamous non-small cell lung cancer. The readout keeps BeiGene’s PD-1 mAb on track as it vies with Innovent’s...

As it looks to roll out what will be at least the sixth marketed PD-1 inhibitor in China, BeiGene hopes the therapy’s differentiated efficacy profile and commercial infrastructure will help the company carve a niche...

Following the nationwide expansion of China’s pilot program for centralized procurement of generics and off-patent originator drugs, Beijing is adding a second group of 33 drugs and unveiling new rules that could increase the number...

Allakos shares jump on report of potential sale Allakos Inc. (NASDAQ:ALLK) declined to comment on a Bloomberg report citing unnamed sources that the company has hired a financial adviser to explore strategic options, including a...

Amgen is taking a hybrid approach to building out its China business that will allow it to accelerate its commercial plans in the country without biting off more than it can chew. Through the deal...